Pulse Biosciences (PLSE) investor relations material

Strategic focus and leadership

• Dedicated to developing Nanosecond Pulsed Field Ablation (nsPFA) for regulated cell death in ablation procedures.

• Leadership team strengthened with new COO and CMO, focusing on electrophysiology (EP) opportunities.

• Board includes experienced industry figures, with recent addition of Maria Sainz.

• Ended Q1 with $68.3 million in cash, supporting a quarterly burn of $15 million.

• Burn rate expected to rise slightly due to increased clinical activity and pivotal study enrollment.

Technology and intellectual property

• nsPFA delivers high-voltage, ultra-short pulses for non-thermal, efficient ablation.

• Protected by 250 patents covering generator, delivery systems, and methods.

• Catheter system integrates into existing workflows, enabling rapid, high-quality lesion formation.

• Next-generation device will combine regional and focal ablation with mapping in a single catheter.

Clinical development and market opportunity

• Focused on large, fast-growing EP ablation market for atrial fibrillation (AFib), with U.S. market expected to double in five years.

• European feasibility study shows 95% efficacy at 6 months and 96% at 12 months for paroxysmal AF ablation.

• U.S. pivotal study enrollment accelerated, with timeline moved up to early Q4.

• Additional IDEs underway for cardiac surgery ablation and thyroid nodule treatment.

• Committed to a partnership-based market entry strategy for capital efficiency.